Preparation: The area for the injection is cleaned, ensuring the procedure is as comfortable and hygienic as possible
FDA's Official Reasons: Lack of Clinical Trials: The FDA emphasizes the need for extensive, controlled clinical trials, which are currently lacking
Furthermore, the absence of standardized formulations complicates dose uniformity and treatment reproducibility, as differences in concentration, excipients, or stability across preparations can materially influence therapeutic efficacy and safety outcomes
This section is informational only and does not claim that BPC-157 or TB-500 treats, cures, or prevents any disease or injury
Kolovrat M, Gojkovic S, Krezic I, Malekinusic D, Vrdoljak B, Kovac KK, et al
Reports of GLP-1-associated gastroparesis have increased as prescribing has expanded